STRATA SKIN SCIENCES INC (SSKN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SSKN • US86272A3059

1.24 USD
+0.08 (+6.9%)
At close: Feb 10, 2026
1.2 USD
-0.04 (-3.23%)
Pre-Market: 2/11/2026, 4:01:57 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall SSKN gets a fundamental rating of 1 out of 10. We evaluated SSKN against 186 industry peers in the Health Care Equipment & Supplies industry. SSKN may be in some trouble as it scores bad on both profitability and health. SSKN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • SSKN had negative earnings in the past year.
  • SSKN had a negative operating cash flow in the past year.
  • SSKN had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: SSKN reported negative operating cash flow in multiple years.
SSKN Yearly Net Income VS EBIT VS OCF VS FCFSSKN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

  • SSKN has a worse Return On Assets (-35.94%) than 61.29% of its industry peers.
  • Looking at the Return On Equity, with a value of -840.18%, SSKN is doing worse than 83.87% of the companies in the same industry.
Industry RankSector Rank
ROA -35.94%
ROE -840.18%
ROIC N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
SSKN Yearly ROA, ROE, ROICSSKN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • With a Gross Margin value of 57.76%, SSKN perfoms like the industry average, outperforming 58.60% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SSKN has declined.
  • SSKN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
SSKN Yearly Profit, Operating, Gross MarginsSSKN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SSKN has been increased compared to 1 year ago.
  • Compared to 5 years ago, SSKN has less shares outstanding
  • Compared to 1 year ago, SSKN has a worse debt to assets ratio.
SSKN Yearly Shares OutstandingSSKN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SSKN Yearly Total Debt VS Total AssetsSSKN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -11.16, we must say that SSKN is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -11.16, SSKN is not doing good in the industry: 76.88% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 10.22 is on the high side and indicates that SSKN has dependencies on debt financing.
  • SSKN has a worse Debt to Equity ratio (10.22) than 86.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.22
Debt/FCF N/A
Altman-Z -11.16
ROIC/WACCN/A
WACC12.1%
SSKN Yearly LT Debt VS Equity VS FCFSSKN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

  • SSKN has a Current Ratio of 0.95. This is a bad value and indicates that SSKN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.95, SSKN is doing worse than 86.02% of the companies in the same industry.
  • SSKN has a Quick Ratio of 0.95. This is a bad value and indicates that SSKN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.75, SSKN is doing worse than 84.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.75
SSKN Yearly Current Assets VS Current LiabilitesSSKN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for SSKN have decreased by -0.38% in the last year.
  • The Revenue has decreased by -5.19% in the past year.
  • SSKN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.22% yearly.
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%

3.2 Future

  • SSKN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.14% yearly.
  • The Revenue is expected to grow by 2.23% on average over the next years.
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue Next Year-9.3%
Revenue Next 2Y-1.15%
Revenue Next 3Y2.23%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SSKN Yearly Revenue VS EstimatesSSKN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
SSKN Yearly EPS VS EstimatesSSKN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • SSKN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SSKN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SSKN Price Earnings VS Forward Price EarningsSSKN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SSKN Per share dataSSKN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • SSKN's earnings are expected to grow with 17.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.43%
EPS Next 3Y17.14%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SSKN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

STRATA SKIN SCIENCES INC

NASDAQ:SSKN (2/10/2026, 8:00:00 PM)

Premarket: 1.2 -0.04 (-3.23%)

1.24

+0.08 (+6.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-25
Inst Owners19.58%
Inst Owner Change-2.63%
Ins Owners0.18%
Ins Owner Change-0.24%
Market Cap7.30M
Revenue(TTM)30.98M
Net Income(TTM)-11.04M
Analysts85
Price Target7.55 (508.87%)
Short Float %6.61%
Short Ratio3.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.02%
Min EPS beat(2)-104.6%
Max EPS beat(2)8.56%
EPS beat(4)1
Avg EPS beat(4)-94.34%
Min EPS beat(4)-271.14%
Max EPS beat(4)8.56%
EPS beat(8)2
Avg EPS beat(8)-98.86%
EPS beat(12)4
Avg EPS beat(12)-57.78%
EPS beat(16)7
Avg EPS beat(16)-39.57%
Revenue beat(2)0
Avg Revenue beat(2)-14.84%
Min Revenue beat(2)-17.42%
Max Revenue beat(2)-12.25%
Revenue beat(4)1
Avg Revenue beat(4)-8.34%
Min Revenue beat(4)-17.42%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-8.04%
Revenue beat(12)4
Avg Revenue beat(12)-5.63%
Revenue beat(16)6
Avg Revenue beat(16)-2.84%
PT rev (1m)0%
PT rev (3m)-7.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.74%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B 5.56
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.67
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.26
BVpS0.22
TBVpS-0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.94%
ROE -840.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.76%
FCFM N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score3
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 10.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.81%
Cap/Sales 5.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.95
Quick Ratio 0.75
Altman-Z -11.16
F-Score3
WACC12.1%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)69.64%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%
Revenue Next Year-9.3%
Revenue Next 2Y-1.15%
Revenue Next 3Y2.23%
Revenue Next 5YN/A
EBIT growth 1Y-4.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.21%
EBIT Next 3Y84%
EBIT Next 5YN/A
FCF growth 1Y47.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.99%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%

STRATA SKIN SCIENCES INC / SSKN FAQ

What is the fundamental rating for SSKN stock?

ChartMill assigns a fundamental rating of 1 / 10 to SSKN.


What is the valuation status for SSKN stock?

ChartMill assigns a valuation rating of 0 / 10 to STRATA SKIN SCIENCES INC (SSKN). This can be considered as Overvalued.


How profitable is STRATA SKIN SCIENCES INC (SSKN) stock?

STRATA SKIN SCIENCES INC (SSKN) has a profitability rating of 1 / 10.


Can you provide the financial health for SSKN stock?

The financial health rating of STRATA SKIN SCIENCES INC (SSKN) is 0 / 10.


What is the expected EPS growth for STRATA SKIN SCIENCES INC (SSKN) stock?

The Earnings per Share (EPS) of STRATA SKIN SCIENCES INC (SSKN) is expected to grow by 29.66% in the next year.